Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Former Israeli judge does not expect Netanyahu to be pardoned - 2NASA astronauts to return from space early due to an 'unexpected medical issue.' What happened — and when are they coming home?
- 3'Yellowstone' made him a fan favorite. His biggest role isn't the one you see.
- 4Pedal Power: Divulging Well known Bike Brands for Each Cyclist
- 5The moon up close: How the Artemis 2 astronauts are photographing their historic lunar flyby
- Dancing through the crackdown: The satirical song soundtracking post-Khamenei Iran
- From Novice to Master: Dominating a Side interest
- Chinese fossils reveal a primordial burst of animal evolution
- Disability rights activist and author Alice Wong dies at 51
- Artemis II astronauts channel Apollo 8 with a striking Earthset photo
- Vote In favor of Your Favored Keeping an eye on
- Popular Film Areas: A Worldwide Manual for Film Enchantment
- Blood pressure drug recalled for possible cross-contamination
- When fake data is a good thing – how synthetic data trains AI to solve real problems
